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Misericórdia de São Paulo, São Paulo, Brazil, 4 Department of Biology, São Paulo State University (UNESP), São José do Rio
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Non-responsiveness to anti-TNF-a therapies presents relevant rates in inflammatory
bowel disease patients, presenting the need to find biomarkers involved in therapeutic
efficacy. Herein, we demonstrate that higher levels of colonic formyl peptide receptor 1
and annexin A1 correlate with histological recovery in Crohn’s disease patients under
remission. Using the dextran sulfate sodium colitis model in mice, we suggest that
infliximab induces annexin A1 expression and secretion in activated intestinal leukocytes.
Conversely, this mechanism might stimulate epithelial formyl peptide receptors, inducing
wound healing and consequent histological remission. Our data indicate that assessing
intestinal expressions of formyl peptide receptors and annexin A1 might provide precious
information on the disease activity and responsiveness to infliximab in inflammatory bowel
disease patients.
Keywords: biomarkers, formyl peptide receptor, annexin A1, infliximab, Crohn’s disease, dextran sodium sulfateINTRODUCTION
Inflammatory bowel diseases (IBDs), mainly Crohn’s disease (CD) and ulcerative colitis (UC), are
characterized by severe gastrointestinal inflammation (1). Biological therapies, such as monoclonal
antibodies and infliximab (IFX), are very effective in inducing remission for moderate-to-severe
IBDs (2, 3). By binding soluble and transmembrane tumor necrosis factor alpha (TNF-a), IFX
attenuates inflammation and decreases the need for surgery (2, 4, 5). However, side effects and non-
responsiveness illuminate the relevance of validating biomarkers to assess therapeutic efficacy (6, 7).
We previously described a possible relationship between the response to IFX and the expression
of annexin A1 (AnxA1) in mice with experimental colitis (8). AnxA1 is a resolutive mediator in
human and experimental conditions such as cardiovascular diseases (9, 10), multiple sclerosis (11),org September 2021 | Volume 12 | Article 7141381
de Paula-Silva et al. FPR/AnxA1 Complement IFX Mechanismsand rheumatoid arthritis (12). AnxA1 is produced by epithelial
cells and secreted by infiltrating leukocytes in IBD patients (13).
Local expression of AnxA1 is pivotal to tissue recovery in CD
and experimental colitis (14–16). Recently, it has been suggested
that low levels of AnxA1 in CD support the uncontrolled
inflammation that perpetuates the disease and that differential
expressions of AnxA1 might allow the identification of disease
severity patterns (14, 17). After cell activation, AnxA1 is
mobilized to the membrane, where it is able to trigger anti-
inflammatory pathways through formyl peptide receptors (FPRs)
(18). FPRs have been increasingly studied in IBD as they
participate in antimicrobial and inflammatory processes. FPR
expression in the gut correlates with pathology during acute
inflammation, but plays a protective role in the chronic phases
(19). FPR1 is a wound closure mediator (20, 21), whereas FPR2
induces mucosal healing by regulating the traffic of leukocytes
into the inflamed tissue (22, 23).
This background provides valuable information about the roles
of AnxA1 in IBD; however, only a couple of studies—including
ours—have addressed the involvement of AnxA1 in the efficacy of
IFX (8, 14). Also, none has explored the potential participation of
the AnxA1–FPR axis. Herein, we describe some IFX mechanisms
that are affected by the AnxA1–FPR axis and seek to explain how it
could mediate distinct responses to anti-TNF-a.MATERIALS AND METHODS
Patient Approach and Ethics Statement
CD patients from the Santa Casa School of Medical Sciences (São
Paulo, Brazil) and donors with no IBD history willingly donated
blood (12 ml). Medical records and paraffinized colon biopsies
provided the CD Activity Index (CDAI) (24) and microscopic
grading (25). This study was conducted in accordance with the
Declaration of Helsinki and the ethics boards from Santa Casa andFrontiers in Immunology | www.frontiersin.org 2the University of São Paulo (protocol #07100819.3.0000.0067).
Written consent was obtained.
Criteria for Patient Enrollment
The diagnosis of CD for patients participating in this study took
into account endoscopic, histological, and clinical criteria
assessed and interpreted by members of the medical staff from
the Santa Casa School of Medical Sciences. Individuals younger
than 18 years and/or with a diagnosis of an infectious disease
(such as tuberculosis, chlamydia, and the common flu)
were excluded.
Participants were divided into groups as follows:
Blood donors: Healthy individuals with no prior history of IBD
provided control samples of blood matching the average age,
gender, and ethnicity from CD groups. “Remission patients”
reached clinical remission upon IFX treatment, while “Failure
patients” were refractory to previous therapies and were not
responding clinically to IFX at the moment of blood donation.
One untreated CD patient provided active disease parameters and
was receiving other medications (including immunosuppressants
and corticosteroids), but not IFX.
Biopsy donors: Remission patients reached clinical and
histological remission when treated with IFX. The Failure group
was composed of patients who did not present improvement of
clinical parameters and histological homeostasis upon IFX. “CD
untreated” individuals were those with an active disease despite
treatment administration of other medications (including
immunosuppressants and corticosteroids), but not IFX.
It should be noted that all patients enrolled in this study had
previously received or were receiving other medication classes at
the time of our sample collection. The absence/interruption of
responsiveness to other therapies followed by remission or non-
remission upon IFX was the defining parameter for separating
the Remission and Failure groups, respectively. Clinical
parameters (mean and range of age, gender, and concomitantTABLE 1 | Characteristics from CDa patients and healthy donors.
Parameters Blood Tissue
Healthy donors CD patients
Untreated Remission Failure Untreated Remission Failure
Average age (mıń.–max.) 32 (23–41) 24 35 (19–50) 39 (19–63) 28 (19–49) 43 (17–44) 38 (61–16)
Standard deviation (age) 10.11 0.00 12.14 14.65 13.96 3.51 31.81
Females 3 1 8 5 3 2 0
Males 2 0 4 7 1 1 2
Total 5 1 12 11 4 3 2
Medications
Corticosteroids – – – 3 (27.3%) 1 (25%) – 1 (50%)
Mesalazine – 1 (100%) 3 (25%) 6 (54.6%) 2 (50%) 2 (66.6%) 1 (50%)
Azathioprine – – 3 (25%) 4 (36.4%) 3 (75%) – 2 (100%)
Anti-diarrheic – – 1 (8.3%) 1 (9.1%) – 1 (33.3%) –
Antidepressants 2 (40%) – 2 (16.6%) – – 1 (33.3%) 1 (50%)
Antibiotics – – – 2 (18.2%) 1 (25%) – –
Hepatics and pancreatics – – – 3 (27.3%) 1 (25%) – 1 (50%)
Hepatics and Hidrocortisone pre-IFXb – – – 1 (9.1%) – – –
Other 2 (40%) 1 (100%) 2 (16.6%) 4 (36.4%) 2 (50%) 1 (33.3%) 2 (100%)September 2021 | Volume 12 | ArtiaCD, Crohn’s disease; bIFX, infliximab.cle 714138
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CD+IFX Failure groups are presented in Table 1.Isolation of Leukocytes and Detection of
AnxA1 in the Blood of CD Patients
Blood from healthy donors (n = 5) and CD patients treated with
IFX (n = 23) or not (n = 1) was used to isolate the following:
Plasma AnxA1: AnxA1 was detected in plasma samples using
an ELISA kit (MyBioSource, San Diego, CA, USA).
Leukocytes: NH4Cl (0.13 M) was added to the remaining cell
fraction to lysate erythrocytes. Pellets were fixed in 1%
paraformaldehyde (PFA) and incubated with anti-FPR1 (PE, R&D
Systems, Minneapolis, MN, USA) and anti-FPR2 (FITC, Bioss,
Woburn, MA, USA) antibodies. Readings were conducted using a
BD Accuri Flow Cytometer (BD Biosciences, Franklin Lakes, NJ,
USA) to acquire 10,000 events/sample. Positive populations were
determined by labeling for each antibody separately.
Detection of AnxA1, FPR1 and FPR2
in CD Biopsies
Paraffin-embedded colon biopsies from CD untreated (n = 4)
and treated positive (n = 3) or negative (n = 2) responders to IFX
were permeabilized (0.01% Triton), retrieved (sodium citrate
buffer), and blocked (20% fetal bovine serum, FBS). Samples
were incubated with mouse anti-FPR1 (1:25, clone 5F1; BD
Biosciences), anti-FPR2 (1:10, clone 2D8; Sigma-Aldrich, St.
Louis, MO, USA), or anti-AnxA1 (1:50, clone 1B, 10 mg/ml).
Incubation with 20% FBS provided the negative control. After
incubation with anti-mouse Alexa Fluor 488 secondary antibody
(1:200; Thermo Fisher, Waltham, MA, USA) and DAPI, the
slides were mounted and five regions of interest (ROIs) per slide
were photographed on a confocal microscope (Zeiss LSM800).
Before acquiring images, the settings for gain, offset, and
exposure time were adjusted based on the reaction control and
standardized for each ROI from the stained samples. Acquired
composite images (.czi format) were imported to Fiji (ImageJ
Software, Bethesda, MD, USA) and split into blue and green
channels. For densitometric analysis, the green channel (Alexa
Fluor 488) was selected and modified to be displayed with a gray
filter. Background pixel averages were then subtracted from the
image pixels of interest to correct uneven illumination with the
aid of the “Process > Math > Subtract” process. Fluorescence
measures were performed manually by the selection of positive
regions; average values were expressed in arbitrary units.Ethics Statement and Animals
C57BL6 wild-type (WT) or AnxA1-null mice (AnxA1−/−), males,
8–10 weeks old, were used to perform colitis. WT C57BL6, males,
16–18 weeks old, were used to provide intestinal immune cells to
ex vivo experiments. Mice were obtained from the Federal
University of São Paulo Animal House (Brazil), kept in 12:12-h
light/dark cycle, and provided with food and water ad libitum.
Experiments were performed in accordance with the Brazilian
laws of protection and approved by the Committee on Ethics of
Animal Experiments from the University of São Paulo.Frontiers in Immunology | www.frontiersin.org 3Colitis Model and Clinical Analysis
Fresh 2% dextran sodium sulfate (DSS; weight/volume, 40 kDa;
Dextran Products Limited, Scarborough, Ontario, Canada) was
added to the drinking water of WT and AnxA1−/− mice (day 0)
and replenished every other day up to day 6 (26). Control and
non-treated DSS mice received vehicle (sterile saline 0.9% +
DMSO 0.5%) intraperitoneally (i.p.) on days 0–9. DSS-treated
groups received i.p. IFX (1 mg/kg; Remicade® Janssen-Cilag,
Buenos Aires, Argentina) on day 1 and/or FPR antagonist Boc-2
(10 mg/kg; N-t-BOC-MET-LEU-PHE, MP Biomedicals, Irvine,
CA, USA) on days 0–9. Body weight, diarrhea, and rectal
bleeding were scored daily to provide the Disease Activity
Index (DAI). On day 10, mice were euthanized by
overexposure to nasal anaesthesia [isoflurane; 2-chloro-2-
(difluoromethoxy)-1,1,1-trifluoro-ethane].
Dosage of Tissue MMP-9
Samples of medium colon were homogenized in RIPA buffer
containing a protease inhibitor (1:100; Thermo Fisher) in an
Ultra-Turrax homogenizer (T10-Basic-IKA). After 20 min on
ice, the tissue debris were removed and matrix metalloproteinase
9 (MMP-9) was detected by ELISA (R&D Systems).
Histological Analysis In Vivo
Distal colons were fixed in 4% buffered PFA, dehydrated, and
embedded in paraffin. Samples were analyzed using high-power
objectives on the Imager.A2 Zeiss microscope (Zeiss,
Oberkochen, Germany).
Histopathology
Histological grading was based on a previous report (8). The
following features were analyzed by a blinded histologist:
changes on crypts and histoarchitecture, edema, ulceration and
immune cells at the epithelium, lamina propria, or submucosa.
Grades of 0, 1, 2, 3, and 4 were respectively attributed to normal,
mild, mild–moderate, moderate–severe, and severe conditions.
Results were expressed as the mean of total grading.
Immunohistochemistry
After permeabilization (Triton 0.01%) and antigen retrieval
(sodium citrate buffer, 10 mM, pH 6.0), peroxidase was
inactivated with 3% hydrogen peroxide. Samples were blocked
with 10% Tris-buffered saline–bovine serum albumin and
incubated with the anti-AnxA1 antibody (1:500; Thermo
Fisher). The reaction control was incubated with a blocking
solution. The slides were finalized with an anti-rabbit
horseradish peroxidase (HRP) antibody (Abcam, Cambridge,
UK), 3,3-diaminobenzidine (DAB; Thermo Fisher), and
hematoxylin counterstaining.
Immunofluorescence
Permeabilized samples were retrieved in sodium citrate buffer
and blocked with 20% FBS. Antibodies were incubated overnight
(4°C): polyclonal mouse anti-b-actin (1:200) and rabbit anti-
villin (1:50; Abcam). After secondary antibodies (anti-mouse
DyLight 549 and anti-rabbit FITC, 1:200; Vector Laboratories,
Burlingame, CA, USA), the nuclei were stained with DAPI.September 2021 | Volume 12 | Article 714138
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Propria and Flow Cytometry
Leukocytes from proximal colonic lamina propria were isolated
after washes with 2 mM EDTA and digestion with collagenase V
from Clostridium histolyticum (1 mg/ml; Sigma-Aldrich) (26).
The cells were washed through 40-mm strainers (Corning,
Corning, NY, USA) and stained with CD4 (FITC) and CD25
(APC) (1:100; BD Biosciences). Positive populations were
determined by labeling with single antibodies. A minimum of
10,000 events per sample were acquired on a BD Accuri Flow
Cytometer. The results were expressed as percentages of positive
cells normalized by controls from each experiment.
Isolation of Colonic Lamina Propria
Leukocytes and Ex Vivo Treatments
After euthanasia by overexposure to isoflurane, colons from
C57BL6 mice were opened longitudinally and washed with
supplemented phosphate-buffered saline (10,000 mg/ml penicillin/
streptomycin and 50 mg/ml gentamycin). Under a sterile hood, the
tissues were fragmented, washed in Hank’s salt solution buffer
without calcium/magnesium for 20 min (twice), and digested with
collagenases from C. histolyticum (types II and IV, 0.5 mg/ml;
Gibco, Waltham, MA, USA). The digested tissue was washed twice
through 40-mm strainers (Corning) and the pellets were counted
and resuspended at the Roswell Park Memorial Institute (RPMI +
1% FBS). Cells were seeded in a 96-well plate (2 × 105/well) and
treated with 200 ng/ml lipopolysaccharide (LPS; Sigma-Aldrich) 30
min before IFX (0.1, 1.0, or 10.0 mg/ml). Controls were untreated or
treated with those IFX doses. After 24 h, the supernatants were
collected to dose secreted AnxA1 (MyBioSource) according to the
manufacturer’s instructions.
Statistical Analysis
To determine the parametric or non-parametric distributions, we
used the Kolmogorov–Smirnov test. ANOVA followed by
Tukey’s was performed for parametric tests, and Kruskal–
Wallis followed by Dunn’s post-test was performed for non-
parametric tests. To compare the two groups, we applied
unpaired (single measures) or paired t-test (repeated
measures). Pearson’s correlation was performed for correlation
analysis, providing the correlation coefficient r and the coefficient
of determination R2. Probabilities with p < 0.05 were considered
significant. The results were expressed as the mean ± standard
deviation (SD; human samples, individual variabilities) or
standard error of the mean (SEM; in vivo/ex vivo assays, group
variability). All statistical assessments were conducted using
GraphPad Prism® software, version 9.1.2 (San Diego, CA, USA).RESULTS
AnxA1 and FPR1 Are Differentially
Expressed in the Colon of CD Patients
Responsive to IFX
Recently, it has been suggested that differential expressions of
AnxA1 might allow the identification of disease severity patternsFrontiers in Immunology | www.frontiersin.org 4in IBD (14, 17). Thus, we proposed screening the expression
patterns of AnxA1 and its receptors, FPR1 and FPR2, in CD
biopsies of colons from untreated and IFX-treated patients who
either went into remission or did not. Information about the
healthy volunteers and CD patients are listed in Table 1.
Hematoxylin/eosin-stained colon biopsies revealed ulcers,
crypt alterations/abscesses, and prominent inflammatory
infiltrates in untreated and IFX Failure patients (Supplementary
Figures 1A, C). Based on the grading system (Supplementary
Table 1), we confirmed lower histological damage for remittent
(Supplementary Figure 1B and Figure 1F) rather than untreated
CD individuals.
Subsequently, FPR1, FPR2, and AnxA1 were detected on the
colon biopsies using confocal microscopy (Figure 1). For those
three markers, the Z-scores were above the population mean for
the IFX-induced remission group, contrasting with the lower
levels in the untreated and IFX Failure groups (Figure 1A).
Despite the increased fluorescence detected for FPR1
(Figures 1C, G) and FPR2 (Figures 1D, H) in remittent
patients, only AnxA1 was significantly higher than that in the
untreated group (Figures 1E, I). Epithelial cells from barrier,
crypts, and leukocytes were the major sources of FPR1, FPR2,
and AnxA1. Furthermore, colonic FPR1 and AnxA1 expressions
presented a strong negative correlation with the histological
grading (Figures 1J, L), which means that the decrease of
these markers is associated with more tissue damage. For
FPR2, a moderate correlation was detected (r = −0.5355), but
this was not enough to characterize a significant association
(Figure 1K). Based on this, we presume that the upregulation of
colonic FPR1 and AnxA1 in CD positive responders to IFX
provides a marker of differential expression for therapy efficacy.
Using the patients’ medical histories, we calculated the CDAI
(Supplementary Table 2). Despite the different intensities of
disease activity among patients, no patterns for circulating FPR1,
FPR2 (leukocytes), or AnxA1 (plasma) were observed for the
healthy, remission, or failure groups (Supplementary Figure 2A).
As expected, CDAI was significantly higher in IFX-unresponsive
patients than in remission patients (Supplementary Figure 2B).
Furthermore, FPR1, FPR2, and AnxA1 in blood did not correlate
with CDAI, indicating that patients’ circulating levels might not be
reliable biomarkers for remission or failure after IFX treatment
(Supplementary Figures 2C–H).
FPR Signaling Complements the Beneficial
Effects of IFX on Colitis Symptomatology
and Tissue Damage
After detecting the correlations between high expressions of
FPR1/AnxA1 and histological recovery in CD, we wondered
how the modulation of these markers would impact resolution
after IFX. We have previously demonstrated the failure of IFX in
treating acute colitis using AnxA1-null Balb/c mice (8). To
explore the mechanisms involved in the efficacy of IFX, we
performed DSS-induced colitis in WT and AnxA1−/− C57BL6
mice and followed up to the late phase of the disease (Figure 2
and Supplementary Figures 3, 4). As expected, colitis induced
significant weight loss and increased the DAI in both WT
(Figures 2A–C) and AnxA1−/− strains (SupplementarySeptember 2021 | Volume 12 | Article 714138
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produced by DSS, including colon shortening, MMP-9 increase,
ulcers, altered crypt, crypt abscesses, vacuolar hydropic
degeneration, submucosal edema, and mucosal/submucosalFrontiers in Immunology | www.frontiersin.org 5massive inflammatory infiltrates (Figures 2D–H and
Supplementary Figures 4E–I). IFX attenuated body weight
loss (days 9 and 10; Figure 2A) and DAI during the late phase
of the disease (day 8; Figures 2B, C) in WT mice. Except forFIGURE 1 | Formyl peptide receptor 1 (FPR1), FPR2, and annexin A1 (AnxA1) are differentially expressed in the colon of Crohn’s disease (CD) responders to
infliximab (IFX) and correlate with histological homeostasis. (A) Heatmap based on the Z-scores of FPR1, FPR2, and AnxA1 expression values in the colon.
(B–E) Confocal imaging: negative control of reaction (B), FPR1 (C), FPR2 (D), and AnxA1 (E) tissue staining. Embedding, paraffin; sections, 3 mm. Bar, 20 mm.
(F) Histological grading, calculated based on Supplementary Table 1. (G–I) Densitometric analysis of fluorescence: FPR1 (G), FPR2 (H), and AnxA1 (I). (J–L)
Correlation analysis between histological grading of biopsies and fluorescence intensity of staining: FPR1 (J), FPR2 (K), and AnxA1 (L). *p < 0.05, **p < 0.01. n = 4
(CD untreated); n = 3 (Remission); n = 2 (Failure). Results are expressed as the mean ± SD.September 2021 | Volume 12 | Article 714138
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the colonic histological architecture was protected by IFX
(Figure 2J). These improvements were not only absent in the
AnxA1−/− group upon IFX treatment (Supplementary Figures
4A, B, J), but anti-TNF-a seemed to be harmful without
endogenous AnxA1 as well: a 50% mortality rate was recorded
(Supplementary Figure 4C). AnxA1-deficient mice had
significant colon shortening (Supplementary Figures 4E, F)
and a 200- to 300-fold increase in tissue MMP-9 with or
without IFX treatment (Supplementary Figure 4G). Moreover,
AnxA1−/−/DSS+IFX mice had less intestinal T regulatory
lymphocytes than did the mice in the respective WT group
and the untreated group (AnxA1−/−/DSS), reaffirming the
relevance of AnxA1 to the downregulation of inflammation
even when TNF-a is being blocked by IFX (Supplementary
Figure 4D).
For the next step, we blocked the AnxA1 receptors, FPRs, to
assess their potential involvement in the effects of IFX. The FPR
blockade, by itself, confirmed their well-known role in wound
healing (15, 27). FPR neutralization was detrimental to the
clinical parameters in both early and late phases of disease
(Figures 2A–C), intensified colon shortening (Figures 2D, E),
and increased MMP-9 (Figure 2F). Microscopically, the FPR
blockade with Boc-2 worsened the DSS damage, especially with
regard to epithelial/glandular loss and infiltrated leukocytesFrontiers in Immunology | www.frontiersin.org 6(Figure 2I). When combined with IFX, blocking FPRs was
detrimental to the clinical conditions in the late phase as the
beneficial effects of IFX on body weight and DAI were lost (days
9 and 10 and day 8 in Figures 2A, B, respectively) (Figure 2C).
Although the colon length and MMP-9 from IFX-treated mice
were not affected by Boc-2 (Figures 2D, E), the cecum very
consistently assumed a distorted morphology and paleness for
this group (Figure 2D).
Finally, the histological parameters were analyzed. IFX-
mediated preservation of the colonic histoarchitecture was
partially impaired by an FPR blockade, with the presence of
immune cells in the mucosa and punctual but persistent
ulcerations (Figure 2K). The clearest histological alteration in
this group was poor crypt recovery (details in Figure 2K). For
this reason, we proceeded to explore the effects of halting the
signaling through FPRs for the regeneration of crypts after
IFX treatment.
Blocking FPRs Compromises the Effects
of IFX on Crypt Regeneration
The relevance of FPRs for crypt regeneration was confirmed by
structural protein immunostaining (Figure 3). In control mice,
b-actin revealed the cylindric shape of enterocytes (Figure 3A,
a1) with villin expressed on the apical surfaces of cells
(Figure 3A, a2). A similar pattern was observed on cryptsFIGURE 2 | Formyl peptide receptor (FPR) blockade impairs clinical and histological improvements induced by infliximab (IFX) during colitis. (A) Loss of body weight.
(B) Disease Activity Index (DAI). (C) Area under the curve from DAI, early and late phases. (D, E) Colon length and anatomic changes. (F) Colonic MMP-9 levels. Mean of
all samples (continuous lines). Bar, 1 cm. aap < 0.01 (DSS vs. Control); bp < 0.05 (DSS+IFX vs. DSS); cp < 0.05 (DSS+Boc-2 vs. DSS); dp < 0.05 (DSS+IFX+Boc-2 vs. DSS);
ep < 0.05, eep < 0.01, eeep < 0.001 (DSS+IFX+Boc-2 vs. DSS+IFX). *p < 0.05, **p < 0.01, ***p < 0.001. n = 4–6 mice/group. Results are expressed as the mean ± SEM.
(G–K) Histopathology in wild-type (WT) groups. Ulcer (black arrows), altered crypts (white arrows), crypt abscesses (white arrowheads), edema (Ed), and inflammatory
infiltrate (circles). Staining, hematoxylin–eosin; embedding, paraffin; sections, 3 mm. Bars, 20 mm.September 2021 | Volume 12 | Article 714138
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possible to identify the secretory and excretory portions from the
mucosal glands, forming a U-shaped structure with a centered
vertical lumen that opens to the intestinal wall, where the
secretions produced by crypts are liberated.
Upon FPR inactivation, with or without IFX treatment, crypt
cells assumed a deformed morphology lacking cylindric limits.
The elongated shape from crypts gave place to an amorphous
structure, many times with the lumen turned into a round form
that was no longer connected with the epithelium surface
(Figure 3C, c1). In this space, we observed residues of the shed
villin (Figure 3C, c2 and c3, green) that co-localized with DNA
(Figure 3C, c2 and c3, blue). FPRs were associated with epithelial
repair, migration, and wound healing before, but our resultsFrontiers in Immunology | www.frontiersin.org 7suggest that these roles are also required for the intestinal barrier
homeostasis mediated by IFX. Considering that AnxA1 is an
important FPR agonist and a pivotal mediator of tissue repair in
IBD, our final step was to assess the possible kinds of interplay
among AnxA1 expression, FPR activation, and IFX efficacy.
IFX Induces AnxA1 Expression and
Secretion by Tissue Leukocytes During
Inflammation
Intracellular and FPR-binding AnxA1 mediate inflammation
resolution and tissue repair on experimental colitis (8, 28). In
our model, we assessed the expression patterns for endogenous
AnxA1 in the colon (Figure 4). The reaction control confirmed
specificity (Figure 4J).FIGURE 3 | Crypt regeneration mediated by infliximab (IFX) requires formyl peptide receptor (FPR) signaling. (A) Control: cylindrical-shaped cells forming a U-shaped
crypt revealed by b-actin staining (a1, red). Presence of villin (a2, green) in the inner surface from the excretory part of the crypt lumen. Representation of a normal
structure. (B) DSS+IFX: preserved crypt morphology resembling the control condition (b1 and b2). (C) DSS+IFX+Boc-2: defects in crypt closure (c1); presence of villin (c2
and c3, white arrowheads); and DNA residue (c2 and c3, black arrowheads) in the crypt lumen. n = 4–6 mice/group. Embedding, paraffin; sections, 3 mm. Bars, 20 mm.September 2021 | Volume 12 | Article 714138
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(Figure 4A). Colitis upregulated AnxA1 in the damaged
epithelium from the DSS and DSS+Boc-2 groups (Figures 4B,
D).Mice treatedwith IFX,withorwithout FPR signaling, presented
epithelial AnxA1 similar to the control group (Figures 4C, E). In
turn,AnxA1wasweaklydetected in tissue leukocytes innon-treated
colitis (Figure 4F). After IFX, a high number of infiltrated AnxA1-
positive immune cells were observed (Figure 4G). AnxA1 was also
detected in leukocytes under Boc-2 (Figure 4H). Interestingly, in
mice treated with IFX and Boc-2, most tissue leukocytes were
negative for AnxA1 (Figure 4I).
Because the intracellular expression of AnxA1 was
upregulated in tissue leukocytes upon IFX, we hypothesized
that transmigrated immune cells could be important sources of
AnxA1 for the inflamed tissue treated with this anti-TNF-a.
Using LPS in vitro assays, we simulated an inflammatory
response in immune cells isolated from the colon of naive
mice. When treated with increasing concentrations of IFX (0.1,
1.0, and 10 µg/ml), we detected a dose-dependent augmentation
in AnxA1 secretion to the milieu (Figure 4K). This phenomenonFrontiers in Immunology | www.frontiersin.org 8was reproduced in the DSS-induced colitis treated with IFX, as
colon explant supernatants had increased levels of AnxA1
compared to the control group (Figure 4L). Finally, we
observed a moderate negative correlation between the secreted
AnxA1 and the grading for histological damage of the colon
(Figure 4M). These results suggest that IFX induces AnxA1
expression and secretion by tissue leukocytes, and this
mechanism is linked to tissue repair.DISCUSSION
Previously, we reported the relevance of AnxA1 in the efficacy of
IFX during acute colitis in female Balb/c mice (8). Here, we
corroborate it using mice of different strain and sex and focusing
on the late phase of disease. On biopsies from CD patients, we
further confirm that IFX modulates AnxA1 in positive
responders. Moreover, we describe FPR1 as a potential marker
of tissue homeostasis after IFX treatment. Our results suggest
that IFX stimulates activated intestinal leukocytes to express andFIGURE 4 | Infliximab (IFX) induces annexin A1 (AnxA1) expression and secretion by infiltrated leukocytes during inflammation. (A–E) AnxA1 expression in the
epithelial barrier from wild-type (WT) mice colon. AnxA1 concentrated on the wound bed (white arrows). (F–I) Immunostaining for AnxA1 in submucosal leukocytes.
Tissue leukocytes positive (black arrowheads) or negative (white arrowheads) for AnxA1 staining. (J) Reaction control. Counterstaining, hematoxylin; embedding,
paraffin; sections, 3 mm. Bars, 20 mm (A–E) and 100 mm (F–I). (K) AnxA1 secreted by lamina propria leukocytes cultured ex vivo. (L) AnxA1 secreted by colon
explants in culture. (M) Moderate negative correlation between AnxA1 secreted into the tissue and histological grading. N.D., non-detected. *p < 0.05, **p < 0.01.
n = 3–4 mice/group (K); n = 4–6 mice/group (L). Results are expressed as the mean ± SEM.September 2021 | Volume 12 | Article 714138
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FPRs and promote tissue repair (29).
Although biologicals are the most successful drug class at
inducing remission among the therapies classically used to treat
IBD (30), they still burden patients with heterogeneous
outcomes, including hypersensitivity, allergies, lack of
responsiveness, or progressive loss of efficacy over the lifetime
(31). Even clinically remittent patients may present remaining
mucosal inflammation associated with severe mucosal disease
activity (32). In response to this, the follow-up protocol for
treated patients proposes the assessment of histological
remission as a more reliable tool to predict a sustained and
steroid-free clinical remission, with lower need for
hospitalization and surgery (33). Herein, we observed a
marked expression of AnxA1 in the colon of CD patients who
underwent remission after IFX. For AnxA1 and FPR1, high
tissue levels correlated with lower histological damage. In a
general manner, the literature on IBD suggests that AnxA1
secretion is evoked during the active disease. Failures in this
mechanism contribute to a more severe and prolonged disease
(26, 34). Similarly, therapeutic interventions have a better
outcome when capable of increasing AnxA1 levels (8, 14). In
the inflamed site, AnxA1 binding to FPRs mediates the
resolution of inflammation and mucosal homeostasis (16, 28).
The data we present here support the mechanisms described
above. Moreover, they suggest that tissue FPR1 and AnxA1 could
constitute useful tools for following up the disease activity and
the efficacy of IFX in CD patients.
Mucosal inflammation begins with the opening of the
epithelial barrier after injury, which allows the translocation of
microbial agents. Once the commensal microbiota is detected by
the immune cells that patrol the tissue, an inflammatory
response is assembled to contain the spreading of bacteria to
the blood and other tissues. However, an unbalanced
inflammation feed-forwards tissue damage and increases
bacterial translocation (35). Upon injury or death, column-
shaped intestinal epithelial cells can lose contact with each
other, assuming a flat morphology. The organism responds by
triggering a proliferation of basal crypt cells and epithelial
migration, promoting wound closure (36). By binding FPRs,
full-length AnxA1 and its peptide, Ac2-26, stimulate the
migration of epithelial cells and wound healing (15, 16). Ac2-
26 binding to FPR1 induces oxidative inactivation of
phosphatase and tensin homolog protein and protein tyrosine
phosphatase-PEST, phosphorylating focal adhesion kinase and
paxillin, consequently stimulating cells to migrate (15).
Additionally, endogenous AnxA1 acts as an anchor between
cytoplasmic b-actin and the plasma membrane, whereas the
AnxA1–FPR2 axis inhibits RhoA GTPase activity, stabilizing
the cytoskeleton (37). Our results confirmed that the lack of
endogenous AnxA1 is very detrimental to the progression of
experimental colitis: AnxA1−/− mice had much worse clinical
and histological outcomes, fewer intestinal regulatory T cell
(Treg) counts, and a 25% mortality rate compared to WT
mice. Preventing AnxA1 and other agonists from binding with
FPRs in vivo was almost equally harmful as all clinicalFrontiers in Immunology | www.frontiersin.org 9parameters were impaired and tissue damage was remarkable,
especially considering crypt and epithelial loss. Interestingly,
treatment with IFX did not compensate for the absence of
endogenous AnxA1 or FPR signaling. The blockade of the
AnxA1–FPR axis impaired crypt restitution, whereas a lack of
AnxA1 impacted the ability of IFX to promote wound healing
and to rebalance the immune response. Based on these data, we
propose that protection of the epithelial barrier with IFX must be
complemented by the downstream pathways resulting from the
binding of AnxA1 (and other endogenous agonists) to
FPRs (Figure 5).
It is well known that the use of IFX on chronic diseases
modulates cellular pathways downstream of TNF receptors
(TNFRs) by blocking soluble and transmembrane TNF-a (38,
39). Considering the complexity of the mechanisms evoked by IFX
and the heterogeneous responses it produces, other endogenous
players are likely to be involved in successful outcomes. Herein, we
suggest that AnxA1 expression might be one mechanism induced
by IFX, which may, in turn, regulate its effects at some level. This
notion is supported by the modulation of intracellular and
secreted AnxA1 after IFX treatment in colitic mice. In colonic
mucosal and submucosal leukocytes activated by inflammatory
mediators, IFX evoked AnxA1 expression. The same group had
increased secretion of AnxA1, which was most likely being
provided by those leukocytes. In line with this, increased levels
of AnxA1 were secreted as higher doses of IFX were added to LPS-
stimulated intestinal leukocytes ex vivo. These results seem to be
translatable to the human condition because we also observed
increased AnxA1 in biopsies from CD patients in association with
histological remission. Indeed, the lack of TNF-a signaling
through TNFR1 in mice during colitis favors tissue AnxA1
expression and increases the frequency of CD4+ and CD8+ T
lymphocytes positive for AnxA1 (26). These data indicate that
intestinal immune cells are the major sources of secreted AnxA1;
this could be one resolutive mechanism of IFX that was not
previously described. Interestingly, the Boc-2 groups had less
secreted AnxA1 with or without IFX. This suggests a more
complex mechanism of action for IFX, in which proper FPR
signaling is required to induce AnxA1 secretion by leukocytes and,
in turn, to mediate tissue repair and wound healing.
Obviously, FPR agonists other than AnxA1 could be involved
in the efficacy of IFX. In the inflammatory milieu, FPR ligands
can be found among endogenous metabolites, peptides, and
damage- and pathogen-associated molecular patterns (DAMPs
and PAMPs, respectively) (40). These include N-formyl-peptides
from mitochondrial damage (41), the antimicrobial peptide LL-
37 and lipoxin A4 (22). It should be noted that the bacterial-
derived peptide formyl-methyl-leucine-phenylalanine (fMLP)
can be present at high concentrations in the wounded
intestinal tissue (42) and binds FPR1 with a strong affinity,
triggering healing pathways on epithelial cells (20, 43). Despite
that, this work addresses AnxA1 participation because of its
pivotal roles in IBD. Our choice was also supported by the
increased AnxA1 secretion upon IFX in experimental colitis and
its correlation with tissue recovery. It is also important to point
out that, although we argue that AnxA1 and FPRs contribute toSeptember 2021 | Volume 12 | Article 714138
de Paula-Silva et al. FPR/AnxA1 Complement IFX Mechanismsthe efficacy of IFX, it is possible that they might be involved in
the effects of other therapies as well. We do not claim that this
modulation is exclusive to IFX, but that it obtains for this specific
therapy. We hope that our study encourages others to explore
therapies that might be complemented by AnxA1–FPR,
elucidating possible mechanisms of therapeutic failure in IBD.
We believe that the data we presented here may contribute to the
identification of poor responsiveness cases, leading to long-term
remission based on the pivotal homeostatic roles of AnxA1
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